Who is sponsoring NCT01151202?

NCT01151202 is sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd.

What drugs are being tested in NCT01151202?

Interventions in NCT01151202: AG NPP709syrup.

What condition does NCT01151202 study?

NCT01151202 studies Acute Upper Respiratory Tract Infections, Bronchitis.

Is NCT01151202 still recruiting?

NCT01151202 is currently completed. Last updated 3 October 2010.

Last reviewed 2010-10-03 · How we verify

NCT01151202

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup" in Acute Upper Respiratory Tract Infection and Chronic Inflammatory Bronchitis Patients: Double Blinded, Randomized, Active Drug Comparative, Parallel Designed, Multi-centered, Phase III Study

Completed Phase 3 Last updated 3 October 2010

What this trial tests

Phase 3 trial testing AG NPP709syrup in Acute Upper Respiratory Tract Infections in 236 participants. Completed in 1 June 2010.

Timeline

1 February 2010

Primary endpoint
1 May 2010

1 June 2010

Quick facts

Lead sponsor	Ahn-Gook Pharmaceuticals Co.,Ltd
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	236
Start date	1 February 2010
Primary completion	1 May 2010
Estimated completion	1 June 2010
Sites	6 locations across South Korea

Drugs / interventions tested

AG NPP709syrup — full drug profile →

Conditions studied

Acute Upper Respiratory Tract Infections — all drugs for Acute Upper Respiratory Tract Infections →
Bronchitis — all drugs for Bronchitis →

Sponsor

Ahn-Gook Pharmaceuticals Co.,Ltd — full company profile →

Who can join

Adults 24 Months to 75, any sex, with Acute Upper Respiratory Tract Infections or Bronchitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

improvement by global assessment
Time frame: 5 days
At closing visit, researcher assess clinical efficacy using the following five criteria (4: cure, 3: significant improvement, 2: improvement, 1: some improvement, 0: non-improvement or worsening of symptoms). Upper the Grade 3 outcomes are defined as "clinical success".

Sponsor's own description

The purpose of this study is to assess therapeutic confirmation of AG NPP709 syrup to evaluate the safety and efficacy in patients with acute upper respiratory tract infection and chronic inflammatory bronchitis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The clinical efficacy of AG NPP709 (Synatura<sup>®</sup>) in patients with chronic bronchitis type stable chronic obstructive pulmonary disease.
Lee EG, Rhee CK. · · 2020 · cited 11× · PMID 32642149 · DOI 10.21037/jtd.2020.03.61
Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms.
Cho YJ, Yoon HJ, Lim DH, Yoo KH, et al · · 2026 · PMID 41807028 · DOI 10.3346/jkms.2026.41.e97

Verify or expand the search:

Other Ahn-Gook Pharmaceuticals Co.,Ltd trials

Trials by the same sponsor.

NCT07198347 — Efficacy and Safety of AG2001 in Patients With Acute Bronchitis · Phase 3 · not yet recruiting
NCT05503953 — Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Contr · Phase 3 · unknown
NCT04686643 — Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension · Phase 3 · unknown
NCT05206578 — Study to Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia · Phase 3 · unknown
NCT04554303 — Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01151202 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahn-Gook Pharmaceuticals Co.,Ltd
Last refreshed: 3 October 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01151202.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing